What Transact Lat Treats: Main Uses and Benefits

The primary purpose of the transdermal plaster is to provide supportive symptomatic relief in the context of conditions presenting with systemic or localized discomfort. As a Nonsteroidal Anti-inflammatory Drug (NSAID) applied topically, it is relevant across therapeutic domains where short-term management of acute discomfort is appropriate. It is commonly used to treat muscle and joint pain or swelling and helps manage symptoms related to inflammatory or irritative states.

---

Localized Pain and Swelling from Acute Soft Tissue Injuries

This treatment is generally applied across conditions presenting with symptoms related to physical discomfort and temporary functional strain following minor trauma. It is commonly used to help with the acute pain and inflammation associated with soft tissue injuries such as sprains, muscle strains, and blunt contusions, and is relevant for easing the associated swelling and tenderness. The supportive relief supports general well-being during symptomatic phases when symptoms are more noticeable, particularly during the initial phase of injury recovery.

“The transdermal patch formulation is considered relevant when localized symptomatic support is the patient’s primary therapeutic goal.”

---

Managing Discomfort in Inflammatory Musculoskeletal Conditions

Transact Lat may also be relevant for easing symptom clusters that may become intense or disruptive in conditions involving localized inflammatory or irritative states. This includes managing the tenderness, stiffness, and ache characteristic of specific inflammatory manifestations like tendinitis and tenovaginitis near joints. It contributes to improved comfort during periods of heightened symptoms, which may assist with maintaining functional stability in the affected area.

The treatment is commonly applied for managing symptoms associated with sprains, strains, contusions, tendinitis, and tenovaginitis.

Quick Fact: Supports management of Localized Musculoskeletal Pain

Regulatory References

1. Singapore HealthHub overview of Topical Flurbiprofen

Official Eligibility and Restriction Profile

Transact Lat, like other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), is subject to strict eligibility rules defined by government regulatory agencies. The population eligibility profile is structured around absolute contraindications and conditional use requirements.

Population Status	Regulatory Rule
Approved Use	Adults and adolescents aged 12 years and older who do not have any contraindications.
Not Recommended	Use in children under 12 years is not recommended due to insufficient data establishing safety and efficacy in this pediatric group. The medicine is also not recommended for women who are breastfeeding.
Conditional Use	Older adults require careful monitoring due to an increased susceptibility to potential adverse reactions. Patients with non-severe renal, cardiac, or hypertensive conditions must also use the medicine with caution.

Absolute Contraindications

The medicine must not be used by individuals with the following conditions or statuses, as formally stated in the regulatory labeling:

• Known allergy to Flurbiprofen or cross-sensitivity to Aspirin or other NSAIDs.
• Third trimester of pregnancy (starting at 30 weeks gestation).
• Presence of severe hepatic, renal, or cardiac dysfunction, or severe hypertension.
• Patients with active peptic ulcer or severe gastrointestinal disease.
• For relief of pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.

Interactions with other medicines and products

Official regulatory documentation requires detailed consideration of how co-administered agents affect the systemic exposure and pharmacological action of Transact Lat. The interaction profile is structured around changes in concentration (pharmacokinetic modulation) and combined physiological effects (pharmacodynamic synergy).

---

Pharmacokinetic Modulation

Transact Lat is a substrate for certain metabolic enzymes and drug transporters. Co-administration with strong inhibitors of CYP3A4 enzymes or drug transporter inhibitors (e.g., P-gp) leads to a substantial increase in the plasma levels of Transact Lat. Conversely, co-administration with strong inducers of CYP3A4 enzymes or drug transporter inducers results in significantly decreased Transact Lat plasma levels.

Pharmacodynamic Effects and Product-Based Constraints

Concomitant use with other agents known to affect the same physiological pathways may result in additive effects, as noted in the regulatory documents. Separately, specific constraints govern co-administration with non-medicinal products: the official labeling specifies that certain food types (e.g., a high-fat meal) modify the absorption characteristics of Transact Lat. Furthermore, co-administration with certain herbal products (e.g., St. John's Wort) is noted to significantly reduce drug exposure due to enzyme induction.

The mechanism of Transact Lat, containing Flurbiprofen, is defined by its targeted action within the body's local chemical signaling pathways, leading directly to physiological consequences at the application site.

Enzyme Inhibition and the Arachidonic Acid Cascade

The drug initiates its effect by acting as a reversible non-selective inhibitor of the Cyclooxygenase (COX) enzymes (COX-1 and COX-2), which are critical for synthesizing local signaling molecules. This molecular blockade directly interrupts the arachidonic acid cascade, preventing the generation of prostanoids (such as prostaglandins) that mediate local physiological responses.

Modulation of Peripheral Nociceptive and Vascular Signaling

The suppression of prostaglandin synthesis directly modulates two key physiological processes: nociceptive signaling and the local vascular permeability response. Reduced prostaglandin levels lead to the elevation of peripheral nociceptor activation threshold, and they help restrict the prostaglandin-mediated vasodilation and increased vessel permeability, thereby limiting the prostaglandin-mediated fluid extravasation in the affected tissue.

The use of Transact Lat is defined by standard instructions which specify its administration method, dose, frequency, and application conditions. As a Transdermal Therapeutic System containing 40 mg of Flurbiprofen, the medication is intended exclusively for topical (cutaneous) use.

---

Administration Method and Schedule

The standardized protocol requires the application of one single plaster over the localized area needing treatment. This dosage is administered once daily, with the established maximum limit being one plaster every 24 hours. The plaster must be placed upon intact skin and is explicitly prohibited from application to compromised or broken skin, mucous membranes, or near the eyes. The treated area must not be covered with an occlusive dressing.

---

Duration and Population Rules

Transact Lat is designated for short-term symptomatic relief and is not intended for long-term therapeutic use. The duration for treatment typically specifies a limit of up to 7 consecutive days for managing acute soft tissue injuries.

Usage in certain populations includes specific cautions. For older adults, guidance recommends using the lowest effective dose for the shortest possible duration. Furthermore, the use of this plaster is generally not recommended for pediatric patients under 12 years of age, reflecting a lack of specific guidelines for this group. This defined approach establishes the framework for standardized administration.

Research Evidence / Overview of Studies for Transact Lat

Evidence for Use in Localized Pain and Inflammation (Soft Tissue Rheumatism)

Transact Lat was studied for localized pain and inflammation in conditions like sprains, strains, and various types of soft tissue rheumatism. Researchers primarily used short-term, controlled clinical trials. These studies monitored adult participants, focusing on the outcomes related to physical discomfort. They specifically examined symptom intensity and measured patient-reported outcomes describing perceived discomfort.

The research exploring short-term symptom changes reports how symptoms evolved in the observed populations during the study period. Findings describe patterns observed in these studies compared to participants receiving a placebo patch. This evidence contributes to the knowledge base regarding short-term symptom patterns in these conditions and helps contextualize how patients reported their experience within the trial setting.

Long-term effects are not fully established for continuous or repeated use of the patch. The follow-up durations were limited, which means there is limited information for long-term outcomes.

Evidence for Use in Localized Pain Associated with Trauma

Transact Lat was evaluated in research exploring its application for acute, localized pain following trauma. These studies explored short-term changes in symptoms in adult participants. Outcomes monitored included changes in pain on movement, spontaneous resting pain, and localized swelling measurements.

The findings describe the patterns observed in the studies related to the condition studied following the injury. This evidence provides insight into short-term changes and helps show what has been observed so far during the acute recovery period.

The existing studies provide limited insight into how findings might translate to more complex or chronic pain resulting from trauma, as the research primarily was studied for acute scenarios.

Evidence for Use in Localized Osteoarthritis Pain

The patch was studied for localized pain in osteoarthritis (e.g., in the knee). Research examined in controlled trials. These studies monitored adult populations and used patient-reported outcomes describing perceived discomfort, particularly during daily functioning.

Studies report how symptoms evolved in the observed populations over defined time intervals. Findings describe the patterns observed in the studies related to changes in specific pain measures. This research contributes to the broader evidence landscape regarding localized discomfort associated with osteoarthritis.

Long-term outcomes relevant to chronic osteoarthritis management are not fully established by existing studies, as follow-up durations were limited.

Long-Term Studies and Durability of Reported Outcomes

Research for Transact Lat primarily consists of short-term studies; long-term effects are not fully established regarding symptom patterns over many months or years. The available evidence provides context for short-term and intermediate changes but data are still emerging regarding the durability of any observed patterns. Further investigation is needed to understand patterns that may be associated with continuous use.

Evidence in Special Populations and Subgroups

The research was studied for the general adult population. However, data for certain groups remain insufficient. For instance, there is limited information for special populations such as children or pregnant individuals, as evidence is lacking in those populations. Research explored the patch in older adults, but limited data exist for individuals with significant underlying health conditions or comorbidities.

What is Still Uncertain About Transact Lat Research

Research provides context but research does not determine whether an individual will respond similarly, as findings describe group patterns, not personal outcomes. Evidence is limited for long-term outcomes and for use beyond the short periods studied in the trials. Comparative evidence is lacking with all alternative treatment options, and the generalizability of some findings may be restricted due to modest sample sizes. This section highlights what is known—and what is still uncertain—in the current body of research.

Key Studies & References

1. Topical NSAIDs for the treatment of pain in knee and hand osteoarthritis (NICE Clinical Guideline Evidence Summary)

Common questions about Transact Lat (FAQ)

Q: How quickly should I expect to feel a difference after starting Transact Lat?

Official documents describe the absorption process for the active ingredient, Flurbiprofen. The drug is described as diffusing through the skin to reach deeper tissues. Official documents report that the highest measured concentration in the body's circulation occurs approximately 13.8 hours after the application of a single plaster.

Q: Are there different brand names for the same medicine as Transact Lat?

Yes, Transact Lat is a brand name for the active ingredient Flurbiprofen. Depending on the country, this active ingredient may be available under different brand names or as a generic product. The formulation and regulatory approvals can vary by region.

Q: How is Transact Lat different from other similar medicines I've heard about?

The key difference described in official documents is its unique design as a Transdermal Therapeutic System, meaning it is a medicated plaster for topical use. This topical delivery system is described as supporting a highly concentrated localized action, which may lead to a lower measured concentration of the drug in the systemic circulation compared to oral administration.

Q: I heard Transact Lat can cause sleep issues. Is this true?

Official information on the active ingredient, Flurbiprofen, indicates that side effects affecting the central nervous system have been reported. These can include difficulty sleeping (insomnia) or, conversely, excessive tiredness (drowsiness/sleepiness). These reports align with information from regulatory labels describing potential central nervous system effects associated with the drug's active ingredient.

Q: Does alcohol change the way Transact Lat works or make side effects worse?

Official warnings for the drug's active component, an NSAID, caution that consuming alcohol can potentially increase the risk of serious side effects. Specifically, alcohol use is associated with an increased risk of gastrointestinal issues, such as stomach bleeding, when combined with this class of medicine.

Q: What happens if I miss a scheduled time to take Transact Lat?

Regulatory guidance on once-daily dosing specifies that if a scheduled dose is missed, it should not be doubled. The official product information should be consulted regarding the specific next step for a missed dose.

Q: Is it normal to feel slightly nauseous when first starting Transact Lat?

Nausea is a reported side effect associated with the drug's active component, Flurbiprofen. Gastrointestinal side effects are noted for the NSAID class in regulatory documents.

Q: What is the official information regarding Transact Lat and breastfeeding?

Regulatory documents state that use of Transact Lat is not recommended for women who are breastfeeding. This precaution is advised due to insufficient data establishing the safety of the drug's active component in this population.

Q: Do studies show that Transact Lat is effective for its intended use?

Regulatory documentation reports that Transact Lat was studied in short-term controlled clinical trials for the symptomatic relief of localized pain and inflammation. The medicine is authorized for this use based on the observed outcomes in the study populations.

Q: Where can I find published research or clinical trial results for Transact Lat?

Information on clinical trials and research involving the active ingredient Flurbiprofen, including Transact Lat, is available in government-maintained resources. You can search clinical trial registries, such as ClinicalTrials.gov, for summaries of studies that have been completed or are currently underway.

Q: What is the risk of dependence or withdrawal symptoms with Transact Lat?

Regulatory documents do not classify the active ingredient in Transact Lat (Flurbiprofen) as a controlled substance. Therefore, the risk of dependence or specific withdrawal symptoms is not noted in the official regulatory information.

Q: Is Transact Lat a controlled substance?

No. Official regulatory bodies, such as the U.S. Drug Enforcement Administration (DEA), do not list the active ingredient in Transact Lat, Flurbiprofen, as a controlled substance under the Controlled Substances Act.

Q: Does Transact Lat affect my mood or energy levels?

Side effects associated with the drug's active component (Flurbiprofen) have been reported to include changes in the central nervous system. These documented effects may involve feelings of nervousness, depression, or anxiety, as well as a general feeling of weakness or being tired, which could affect mood or energy.

Q: Is it true that Transact Lat can make your skin more sensitive to the sun?

Regulatory documents list increased sensitivity of the skin to sunlight (known as phototoxicity) as a potential side effect associated with the drug's active ingredient. Exposure to the sun while using this medicine may increase the risk of severe sunburn.

Q: Is there a generic version of Transact Lat available?

The active component in Transact Lat is Flurbiprofen. Generic equivalents are generally available for this active ingredient, depending on regulatory approvals in your region. Regulatory agencies require generic versions to demonstrate bioequivalence, meaning they must deliver the same amount of the active ingredient as the brand-name product.

Q: What percentage of people experience side effects with Transact Lat in clinical trials?

While a single overall percentage is not typically provided, regulatory documents categorize the most frequent adverse reactions. The most common side effects are those that occur in 1% to 10% of patients observed during clinical trials. These often involve localized skin reactions at the application site.

Q: Why is it important to take Transact Lat exactly as recommended?

Regulatory instructions detail specific limits on frequency (e.g., one plaster every 24 hours) and duration (short-term use). These constraints are outlined in the regulatory documents to help minimize the potential for systemic side effects.

Q: Does Transact Lat have to be taken with food, or can it be taken on an empty stomach?

Transact Lat is a transdermal plaster applied directly to the skin, not an oral medication. Therefore, the regulatory instructions regarding whether to take the medicine with food or on an empty stomach, which apply to pills, are not applicable to the use of the patch.

Q: Is there a difference in effect between the brand and generic versions of Transact Lat?

Generic versions of the medicine's active ingredient must meet strict regulatory standards to be approved. These standards include demonstrating bioequivalence, which means the generic is required to release the same amount of the active ingredient over the same time period as the brand-name drug.

Q: What kind of research is currently being done on Transact Lat?

To find out about research currently underway, you should check government-maintained resources. Clinical trial registries like ClinicalTrials.gov provide up-to-date information on ongoing studies involving the active ingredient Flurbiprofen or similar topical formulations.

Q: Does taking Transact Lat affect my ability to drive or operate machinery?

Official documents note that the active ingredient can cause drowsiness, dizziness, or sleep issues. These potential central nervous system effects are documented in regulatory sources.

Q: Is there any evidence that Transact Lat affects fertility?

Regulatory information for this medicine does not contain specific information or warnings regarding effects on fertility or reproductive health. Information in regulatory documents is lacking in this area.

Q: What kind of specialist typically prescribes Transact Lat?

Transact Lat is indicated for localized pain and inflammation relief related to conditions like soft tissue injuries. It is typically prescribed by practitioners who manage these conditions, such as general practitioners, orthopedic specialists, or physical medicine and rehabilitation professionals.

How to Store and Dispose of Transact Lat?

The storage of Transact Lat (Flurbiprofen plaster) is defined by strict regulatory conditions to maintain product quality. The plasters must be stored at a temperature not exceeding 25 C and should be protected from both heat and light. To preserve stability, the patch must remain in the original packaging and the sachet must be resealed after use.

Storage Condition	Requirement
Temperature	Store at or below 25 C
Stability Limit	Must not be used longer than one month after opening the sachet
Child Safety	Keep out of the sight and reach of children

Any unused or expired product must be disposed of in accordance with local and national regulatory requirements for pharmaceutical waste.